STOCK TITAN

Vanguard disaggregates holdings after internal realignment (ABBV)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 12 to a Schedule 13G/A reporting 0% ownership of AbbVie Inc. The filing states an 0 amount of common shares beneficially owned and shows 0% of the class. The filing explains an internal realignment completed January 12, 2026 that caused certain Vanguard subsidiaries/divisions to report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.

Positive

  • None.

Negative

  • None.

Insights

Amendment shows disaggregated reporting after Vanguard realignment; no beneficial ownership in AbbVie is reported.

The Vanguard Group reports an 0 share position and 0% ownership of AbbVie common stock in this Amendment No. 12 filing. The filing attributes the change to an internal realignment effective January 12, 2026 and cites SEC Release No. 34-39538 (January 12, 1998) as the basis for disaggregated reporting by subsidiaries or business divisions.

Cash‑flow treatment and trading activity are not disclosed in the excerpt; future holdings by individual Vanguard entities will appear in separate 13G/A filings under the referenced Release. Subsequent filings from Vanguard entities may show any active positions.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026

FAQ

What does Vanguard report for ABBV ownership in this Schedule 13G/A amendment?

The filing reports 0 shares beneficially owned and 0% of AbbVie's common stock. The amendment states the amount beneficially owned as 0 and percent of class as 0% in the Ownership section.

Why did Vanguard change its ownership reporting for ABBV?

Vanguard cites an internal realignment effective January 12, 2026. Per the filing, certain subsidiaries/divisions will report separately in reliance on SEC Release No. 34-39538 (January 12, 1998), causing disaggregated filings.

Who signed the Schedule 13G/A amendment for Vanguard (ABBV)?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 03/26/2026. The signature block lists Vanguard's Malvern, PA address.

Does this amendment show any shares held by Vanguard subsidiaries for ABBV?

This amendment states Vanguard itself reports 0 shares and 0%. The filing explains subsidiaries/divisions will report separately; any subsidiary holdings would appear on their own 13G/A filings.
Abbvie Inc

NYSE:ABBV

View ABBV Stock Overview

ABBV Rankings

ABBV Latest News

ABBV Latest SEC Filings

ABBV Stock Data

373.42B
1.77B
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NORTH CHICAGO